Confirmation of the primary endpoint and successful application of Remestemcel-L as a therapy for an unmet need in the US just about books it as a high chance of success of application for FDA accelerated approval according to the Cures Act.
now for LVAD and BACK PAIN
all you can do is tick the boxes and eventually the $$$ will come
Ann: Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial, page-30
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 72752 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 205100 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |